CORDIS
EU research results

CORDIS

English EN
Rapid, robust & scaleable platform technology for fully automated reference laboratory grade Polymerase Chain Reaction (PCR) based diagnostics regardless of global setting

Rapid, robust & scaleable platform technology for fully automated reference laboratory grade Polymerase Chain Reaction (PCR) based diagnostics regardless of global setting

Objective

RANGER addresses the HEALTH-2007-2.3.3-4: Innovative point-of-care (POC) diagnostic tests for influenza call by providing a innovative solution to the immediate need for a rapid, robust, cost effective & user friendly POC diagnostic for influenza. We will develop the following real-time PCR system: 1) A robust, portable system allowing testing at the POC anywhere in the world 2) Raw sample to result automation of the entire test process including sample preparation 3) Parallel processing of multiple samples & different sample types (aspirates & swabs) in a modular, user-friendly system 4) RAPID & simple positive/negative result to the end user 5) No need for an external computer or laboratory equipment 6) Low cost consumable & reagents with a target cost of < €10 per test 7) Sample preparation & freeze dried reagents pre-packaged into an ambient stable consumable to eliminate cold storage chains 8) High confidence PCR results providing sensitivity & specificity equivalent to reference laboratory assays a. Suitable for the diagnosis of early stage infections where viral titres can be low b. Applicable to late surveillance & can be used to confirm the results from lower cost, low performance screen tests such as antibody assays that have low sensitivity and specificity. c. Simultaneous identification of specific influenza strains & viral subtypes using multiplexing real-time PCR assays will also allow exclusion of related respiratory diseases 9) Surveillance Management software & geographical data using GPS, allowing health authorities to manage early stage epidemics. The RANGER consortium includes WHO reference sites for human influenza diagnostics & world leading companies to develop and validate a POC influenza diagnostic system within 2 years. This system will allow health systems to be better prepared for epidemics by enabling early identification of infection and thus timely implementation of containment/treatment strategies.

Coordinator

ENIGMA DIAGNOSTICS LIMITED

Address

Tetricus Science Park Porton Down Building 224
Sp4 0jq Salisbury

United Kingdom

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 1 315 834

Administrative Contact

Ian George (Dr.)

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

Tico Europe Limited

United Kingdom

EU Contribution

€ 31 736

Public Health England an Executive Agency of the Dept of Health

United Kingdom

EU Contribution

€ 468 451

BRUHN NEWTECH AS

Denmark

EU Contribution

€ 62 850

QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH

Thailand

EU Contribution

€ 209 557

BIOPLASTICS BV

Netherlands

EU Contribution

€ 160 841

SAGENTIA GROUP LIMITED

United Kingdom

EU Contribution

€ 431 090

PERA INNOVATION LIMITED

United Kingdom

EU Contribution

€ 225 529

BIOPHARMA TECHNOLOGY LTD

United Kingdom

EU Contribution

€ 76 312

Project information

Grant agreement ID: 201569

Status

Closed project

  • Start date

    1 July 2008

  • End date

    30 June 2011

Funded under:

FP7-HEALTH

  • Overall budget:

    € 4 170 658,60

  • EU contribution

    € 2 982 200

Coordinated by:

ENIGMA DIAGNOSTICS LIMITED

United Kingdom